COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment diseases such as cancer or infectious and autoimmune diseases, today announced that the company is scheduled to present next Monday, 7 January at 8 am PT in the Elizabethan C/D Ballroom of the Westin St. Francis Hotel at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Kirsten Drejer, Ph. D., Chief Executive Officer of Symphogen, will provide a company overview. To access Dr. Drejer’s presentation, please visit Symphogen’s website at www.Symphogen.com
About Symphogen A/S
Symphogen leads the biopharma industry in developing antibody mixtures and products that target multiple oncology targets in a single drug product. Symphogen has established drug discovery, pre-clinical and clinical drug development capabilities and infrastructure, and is expanding in the cancer biology arena to support creation of a pipeline of new cancer therapeutics, providing significant benefit to patients. During 2012 Symphogen out-licensed its lead oncology product, Sym004, a novel antibody mixture targeting the epidermal growth factor receptor (EGFR), to Merck KGaA. Symphogen, founded in 2000 and backed by leading international investors, is based in Copenhagen, Denmark and has a US affiliate based in Princeton, New Jersey.